|Slideshows|April 27, 2016

In This Issue: Volume 33, No. 3

Check out what's new in schizophrenia research, personality disorders, patient education, integrative psychiatry, addiction, and more.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

ByLeah Kuntz

June 29th 2026

Metabolic Risk, Residual Insomnia, and Seltorexant

ByJane Tiller, MD

June 25th 2026

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

BySusan Hatters Friedman, MD, MSt, DFAPA,Ashley A. Mulvihill, MD

June 25th 2026

Seltorexant as Adjunctive Therapy for MDD With Insomnia

ByJane Tiller, MD

June 24th 2026

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

ByLeah Kuntz

June 22nd 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

In This Issue: Volume 33, No. 3

Related Content

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

Metabolic Risk, Residual Insomnia, and Seltorexant

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

Seltorexant as Adjunctive Therapy for MDD With Insomnia

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

Podcast: Practical Insights Into the Evolving Treatment of Bipolar Disorder With David Dunner, MD, FACPsych

New Phase 3 Post Hoc Analyses of Centanafadine for the Treatment of Adults With ADHD

June 2026 in Review: Updates on the Psychiatric Treatment Pipeline